Web-Books
in the Austria-Forum
Austria-Forum
Web-Books
Naturwissenschaften
Chemie
Cancer Nanotheranostics - What Have We Learnd So Far?
Page - 117 -
  • User
  • Version
    • full version
    • text only version
  • Language
    • Deutsch - German
    • English

Page - 117 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Image of the Page - 117 -

Image of the Page - 117 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Text of the Page - 117 -

Alcantaraet al. Molecular imagingofbreast cancer Waterton, J. C., and Pylkkanen, L. (2012). Qualification of imaging biomark- ers for oncology drug development. Eur. J. Cancer 48, 409–415. doi: 10.1016/j.ejca.2011.11.037 Weissleder, R. (2006).Molecular imaging in cancer. Science 312, 1168–1171. doi: 10.1126/science.1125949 Yamaguchi, K., Abe, H., Newstead, G., Egashira, R., Nakazono, T., Imaizumi, T., et al. (2014). Intratumoral heterogeneity of the distribution of kinetic parameters in breast cancer: comparison based on the molecular subtypes of invasive breast cancer. Breast Cancer 1–7. doi: 10.1007/s12282-013- 0512-0. [Epubaheadofprint]. Yan,C.,Wu,Y., Feng, J.,Chen,W.,Liu,X.,Hao,P., et al. (2013).Anti-alphavbeta3 antibodyguided three-steppretargetingapproachusingmagnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int. J. Nanomedicine8,245–255.doi:10.2147/IJN.S38678 Zhou, Z., and Lu, Z. R. (2013). Gadolinium-based contrast agents formagnetic resonance cancer imaging.Wiley Interdiscip. Rev.Nanomed.Nanobiotechnol.5, 1–18.doi:10.1002/wnan.1198 Conflict of Interest Statement:The authors declare that the research was con- ducted in the absence of any commercial or financial relationships that could be construedasapotential conflictof interest. Received: 15 October 2014; accepted: 01 December 2014; published online: 18 December2014. Citation:AlcantaraD, LealMP,García-Bocanegra I andGarcía-MartinML (2014) Molecular imagingofbreastcancer:presentandfuturedirections.Front.Chem.2:112. doi: 10.3389/fchem.2014.00112 Thisarticlewas submitted toChemicalEngineering,a sectionof the journalFrontiers inChemistry. Copyright © 2014 Alcantara,Leal,García-BocanegraandGarcía-Martin.This isan open-access article distributedunder the terms of theCreativeCommonsAttribution License (CCBY).Theuse, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are creditedand that the original publica- tion in this journal is cited, in accordance with accepted academic practice. No use, distributionor reproduction ispermittedwhichdoesnot complywith these terms. www.frontiersin.org December2014 |Volume2 |Article112 | 117
back to the  book Cancer Nanotheranostics - What Have We Learnd So Far?"
Cancer Nanotheranostics What Have We Learnd So Far?
Title
Cancer Nanotheranostics
Subtitle
What Have We Learnd So Far?
Authors
João Conde
Pedro Viana Baptista
Jesús M. De La Fuente
Furong Tian
Editor
Frontiers in Chemistry
Date
2016
Language
English
License
CC BY 4.0
ISBN
978-2-88919-776-7
Size
21.0 x 27.7 cm
Pages
132
Keywords
Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
Categories
Naturwissenschaften Chemie
Web-Books
Library
Privacy
Imprint
Austria-Forum
Austria-Forum
Web-Books
Cancer Nanotheranostics